|
Market Cap | 155.67M | EPS (ttm) | -2.10 |
P/E | - | EPS this Y | 15.78% |
Forward P/E | - | EPS next Y | 39.84% |
PEG | - | EPS past 5Y | 60.98% |
P/S | - | EPS next 5Y | 15.00% |
P/B | 23.82 | EPS Q/Q | 75.06% |
Dividend | - | Sales Q/Q | - |
Insider Own | 24.65% | Inst Own | 19.82% |
Insider Trans | 0.24% | Inst Trans | 1.44% |
Short Float | 2.72% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 22.57 |
Avg Volume | 91.29K | 52W Range | 3.03 - 10.30 |
|
|
|
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Stewart Richard Alistair | Executive Chairman | Mar 04 '24 | Buy | 4.58 | 10,000 | 45,850 | 38,501 | Mar 06 04:49 PM | Bencich John | CEO | Mar 04 '24 | Buy | 4.58 | 10,000 | 45,850 | 76,724 | Mar 06 04:43 PM | Bencich John | CEO | May 30 '23 | Buy | 5.50 | 5,000 | 27,500 | 66,730 | Jun 01 05:42 PM | Stewart Richard Alistair | Executive Chairman | Apr 28 '23 | Option Exercise | 0.00 | 5,000 | 0 | 30,751 | May 01 05:51 PM | Bencich John | CEO | Apr 28 '23 | Option Exercise | 0.00 | 7,500 | 0 | 63,557 | May 01 05:53 PM |
|
|
|
|
Market Cap | 103.22M | EPS (ttm) | -3.71 |
P/E | - | EPS this Y | 133.08% |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 69.84% |
P/S | 0.37 | EPS next 5Y | 12.40% |
P/B | 1.07 | EPS Q/Q | -3068.62% |
Dividend | - | Sales Q/Q | -43.98% |
Insider Own | 12.72% | Inst Own | 49.44% |
Insider Trans | 0.00% | Inst Trans | -4.61% |
Short Float | 0.12% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 20.00 |
Avg Volume | 7.56K | 52W Range | 7.20 - 11.19 |
|
|
|
Ascent Industries Co. engages in the production of stainless steel pipes, stainless and carbon steel piping systems, and specialty chemicals. It operates through the Metals and Specialty Chemicals segments. The Metals segment operates as Bristol Metals LLC (BRISMET), Palmer of Texas Tanks, Inc. (Palmer), and Specialty Pipe & Tube, Inc. (Specialty). BRISMET manufactures welded pipes, primarily from stainless steel, but also from other corrosion-resistant metals. Palmer manufactures fiberglass and steel storage tanks for the oil and gas, waste water treatment, and municipal water industries. Specialty distributes hot finish, seamless, carbon steel pipes and tubing. The Specialty Chemicals segment operates as Manufacturers Chemicals, LLC, which produces chemicals for the chemical, paper, metals, mining, agricultural, fiber, paint, textile, automotive, petroleum, cosmetics, mattress, furniture, janitorial and other industries. The company was founded in 1945 and is headquartered in Oak Brook, IL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Zuppo John Robert III | Exec VP - Ascent Chemicals | Jun 20 '23 | Sale | 9.28 | 957 | 8,881 | 3,503 | Jun 20 04:14 PM |
|
|
|
|
Market Cap | 110.36M | EPS (ttm) | 0.12 |
P/E | 11.35 | EPS this Y | -100.00% |
Forward P/E | - | EPS next Y | -50.00% |
PEG | - | EPS past 5Y | 73.41% |
P/S | 5.17 | EPS next 5Y | - |
P/B | 7.32 | EPS Q/Q | 158.07% |
Dividend | - | Sales Q/Q | -38.71% |
Insider Own | 33.12% | Inst Own | 9.32% |
Insider Trans | 0.00% | Inst Trans | 59.52% |
Short Float | 4.92% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 4.12 |
Avg Volume | 212.06K | 52W Range | 1.04 - 2.16 |
|
|
|
American Resources Corp. engages in the extraction, processing, transportation, and distribution of metallurgical coal to the steel industry. It focuses on the operation of coal mining complexes located primarily within Pike, Knott, and Letcher Counties, Kentucky, and Wyoming County, West Virginia. The company was founded in 2006 and in headquartered in Fishers, IN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Taylor Kirk Patrick | Chief Financial Officer | Jun 15 '23 | Buy | 1.74 | 1,250 | 2,175 | 1,624,883 | Jun 16 09:05 AM | Taylor Kirk Patrick | Chief Financial Officer | May 23 '23 | Buy | 1.57 | 1,250 | 1,961 | 1,623,633 | May 24 03:47 PM | Jensen Mark C. | Chief Executive Officer | May 10 '23 | Buy | 1.55 | 5,000 | 7,746 | 5,199,896 | May 10 03:53 PM | Jensen Mark C. | Chief Executive Officer | Apr 11 '23 | Buy | 1.25 | 5,000 | 6,245 | 5,194,896 | Apr 12 09:30 AM |
|
|
| |
|
Market Cap | 32.05M | EPS (ttm) | -15.60 |
P/E | - | EPS this Y | 39.41% |
Forward P/E | - | EPS next Y | 46.20% |
PEG | - | EPS past 5Y | -80.64% |
P/S | 3.49 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 17.54% |
Dividend | - | Sales Q/Q | 7.00% |
Insider Own | 49.19% | Inst Own | 11.64% |
Insider Trans | 0.08% | Inst Trans | 81.65% |
Short Float | 2.94% | Earnings | Mar 28/a |
Analyst Recom | 2.33 | Target Price | 5.60 |
Avg Volume | 34.95K | 52W Range | 2.31 - 6.75 |
|
|
|
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Sandford Nicole | President & CEO | Dec 06 '23 | Buy | 3.36 | 5,000 | 16,800 | 58,703 | Dec 06 05:21 PM | Merchant Minh Hoang | Secretary & General Counsel | Dec 06 '23 | Sale | 3.37 | 980 | 3,303 | 0 | Dec 08 05:28 PM | Hombeck Torsten | Chief Financial Officer | Sep 08 '23 | Buy | 4.30 | 2,246 | 9,658 | 3,000 | Sep 12 06:37 PM | SCHULER JACK W | 10% Owner | Jul 24 '23 | Buy | 2.75 | 181,800 | 499,950 | 1,883,656 | Jul 25 05:39 PM | Sandford Nicole | President & CEO | Jul 24 '23 | Buy | 3.98 | 12,563 | 50,001 | 134,665 | Jul 25 05:16 PM |
|
|
|
|
Market Cap | 20.07M | EPS (ttm) | -6.12 |
P/E | - | EPS this Y | 56.96% |
Forward P/E | - | EPS next Y | 29.39% |
PEG | - | EPS past 5Y | 8.41% |
P/S | 1.67 | EPS next 5Y | 30.00% |
P/B | - | EPS Q/Q | 103.42% |
Dividend | - | Sales Q/Q | 11.45% |
Insider Own | 39.92% | Inst Own | 11.88% |
Insider Trans | -0.03% | Inst Trans | - |
Short Float | 2.36% | Earnings | Mar 28/a |
Analyst Recom | 2.00 | Target Price | 2.00 |
Avg Volume | 127.00K | 52W Range | 0.83 - 11.90 |
|
|
|
Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Patience David | Chief Financial Officer | Feb 26 '24 | Option Exercise | 0.00 | 1,000 | 0 | 26,597 | Feb 27 06:59 PM | Patience David | Chief Financial Officer | Feb 26 '24 | Sale | 0.96 | 350 | 336 | 26,247 | Feb 27 06:59 PM | Phillips Jack | Chief Executive Officer | Feb 01 '24 | Option Exercise | 0.00 | 1,000 | 0 | 77,201 | Feb 02 04:48 PM | Phillips Jack | Chief Executive Officer | Feb 01 '24 | Sale | 1.30 | 494 | 642 | 76,707 | Feb 02 04:48 PM | Patience David | Chief Financial Officer | Dec 13 '23 | Option Exercise | 0.00 | 331 | 0 | 9,028 | Dec 14 05:14 PM |
|
|
| |
|
Market Cap | 44.06M | EPS (ttm) | -3.53 |
P/E | - | EPS this Y | 23.56% |
Forward P/E | 222.40 | EPS next Y | 100.66% |
PEG | - | EPS past 5Y | - |
P/S | 4.55 | EPS next 5Y | 20.00% |
P/B | - | EPS Q/Q | 36.22% |
Dividend | - | Sales Q/Q | 112.47% |
Insider Own | 69.62% | Inst Own | 9.11% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 2.21% | Earnings | Mar 28/a |
Analyst Recom | 2.60 | Target Price | 7.62 |
Avg Volume | 26.74K | 52W Range | 2.38 - 8.90 |
|
|
|
Cepton, Inc. engages in the development and commercialization of light detection and ranging (lidar) and imaging technologies. It produces lidar sensors for automotive and smart infrastructure industries. The company was founded by Mark McCord and Jun Pei in April 2016 and is headquartered in San Jose, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Qiu Ming | Controller | Aug 21 '23 | Sale | 0.56 | 21,057 | 11,792 | 266,117 | Aug 22 05:59 PM | Han Liqun | Chief Operating Officer | Aug 21 '23 | Sale | 0.56 | 18,673 | 10,457 | 512,855 | Aug 22 06:00 PM | Pei Jun | CEO and President | Aug 10 '23 | Sale | 0.78 | 250,000 | 195,000 | 25,704,268 | Aug 11 06:01 PM |
|
|
|
|
Market Cap | 508.01M | EPS (ttm) | 0.11 |
P/E | 42.92 | EPS this Y | 90.91% |
Forward P/E | 15.66 | EPS next Y | 48.43% |
PEG | - | EPS past 5Y | - |
P/S | 0.44 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -137.66% |
Dividend | - | Sales Q/Q | -5.04% |
Insider Own | 89.71% | Inst Own | 2.79% |
Insider Trans | -0.03% | Inst Trans | -1.55% |
Short Float | 17.93% | Earnings | Mar 28/a |
Analyst Recom | 2.67 | Target Price | 4.59 |
Avg Volume | 128.27K | 52W Range | 1.21 - 6.86 |
|
|
|
Torrid Holdings, Inc. operates e-Commerce platform for apparel and intimates. It offers direct-to-consumer brand of womens plus-size apparel and intimates. The firm products include tops, denim, dresses, intimates, active wear, footwear and accessories. The company was founded in 2015 and is headquartered in City of Industry, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Nikolov Valeria Rico | Director | Jan 16 '24 | Sale | 5.62 | 25,380 | 142,636 | 51,457 | Jan 18 04:42 PM | Mizicko Mark | Chief Commercial Officer | Sep 21 '23 | Buy | 1.33 | 225,000 | 299,520 | 2,321,987 | Sep 25 04:56 PM |
|
|
| |
|
Market Cap | 32.12M | EPS (ttm) | -0.05 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 1.18 | EPS next 5Y | - |
P/B | 1.14 | EPS Q/Q | -1279.79% |
Dividend | - | Sales Q/Q | -23.21% |
Insider Own | 19.92% | Inst Own | 22.07% |
Insider Trans | 21.90% | Inst Trans | -0.71% |
Short Float | 0.63% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 16.00 |
Avg Volume | 10.68K | 52W Range | 3.93 - 13.99 |
|
|
|
CVD Equipment Corp. engages in the design, development, and manufacture of chemical vapor deposition, gas control, and other state-of-the-art equipment and process solutions. It operates through the following segments: Chemical Vapor Deposition (CVD), Stainless Design Concepts (SDC), CVD Materials, and Corporate. The Chemical Vapor Deposition segment is utilized for chemical Vapor deposition equipment manufacturing. The Stainless Design Concepts segment includes ultra-high purity manufacturing division in Saugerties, New York for gas control systems. The CVD Materials segment offers material coatings for aerospace, medical, electronic, and other application. The Corporate segment refers to the firm's administration activities. Its services include anti-corrosion, application lab, collaboration, customer support, printed electronics, fabricated quartzware, and process software. The firm serves the aerospace, glass coatings, medical, military, nanomaterials, optoelectronics, semiconductor, and solar photovoltaics markets. The company was founded by Leonard A. Rosenbaum on October 13, 1982 and is headquartered in Central Islip, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
AFRICK ANDREW | 10% Owner | Dec 01 '23 | Buy | 4.78 | 53,551 | 255,974 | 1,076,834 | Dec 01 08:26 PM | AFRICK ANDREW | 10% Owner | Nov 30 '23 | Buy | 4.51 | 42,659 | 192,392 | 1,023,283 | Dec 01 08:26 PM | AFRICK ANDREW | 10% Owner | Nov 16 '23 | Buy | 5.61 | 62,000 | 347,820 | 980,624 | Nov 17 01:59 PM | AFRICK ANDREW | 10% Owner | Nov 15 '23 | Buy | 5.51 | 85,837 | 472,962 | 918,624 | Nov 17 01:59 PM | AFRICK ANDREW | 10% Owner | Aug 22 '23 | Buy | 7.00 | 12,195 | 85,365 | 832,787 | Aug 23 04:00 PM |
|
|
|
|
Market Cap | 48.31M | EPS (ttm) | -0.47 |
P/E | - | EPS this Y | 52.14% |
Forward P/E | 1.17 | EPS next Y | 350.75% |
PEG | - | EPS past 5Y | 36.56% |
P/S | 48.31 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -10.14% |
Dividend | - | Sales Q/Q | - |
Insider Own | 1.75% | Inst Own | 6.70% |
Insider Trans | 0.00% | Inst Trans | 1.51% |
Short Float | 0.47% | Earnings | Mar 28/a |
Analyst Recom | 1.40 | Target Price | 4.50 |
Avg Volume | 424.67K | 52W Range | 0.27 - 1.10 |
|
|
|
Dare Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA. |
|
|
|
Market Cap | 124.52M | EPS (ttm) | -1.41 |
P/E | - | EPS this Y | 6.97% |
Forward P/E | - | EPS next Y | 25.82% |
PEG | - | EPS past 5Y | - |
P/S | 2.44 | EPS next 5Y | - |
P/B | 0.37 | EPS Q/Q | 58.02% |
Dividend | - | Sales Q/Q | 4.79% |
Insider Own | 12.27% | Inst Own | 30.84% |
Insider Trans | 0.81% | Inst Trans | -1.43% |
Short Float | 21.25% | Earnings | Mar 28/a |
Analyst Recom | 1.00 | Target Price | 2.83 |
Avg Volume | 1.07M | 52W Range | 0.60 - 4.59 |
|
|
|
Danimer Scientific, Inc. operates as a next generation bioplastics company. It focuses on the development and production of biodegradable materials. The firm sells its products under the brand name Nodax. Its applications for biopolymers include additives, aqueous coatings, fibers, filaments, films, and injection-molded articles. The company was founded on January 13, 2014 and is headquartered in Bainbridge, GA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
HENDRIX RICHARD J | Director | Nov 28 '23 | Buy | 0.94 | 50,000 | 46,915 | 50,000 | Nov 28 05:35 PM | HENDRIX RICHARD J | Director | Nov 28 '23 | Buy | 0.93 | 50,000 | 46,480 | 391,324 | Nov 28 05:35 PM | Tuten Scott | Chief Marketing Officer | Jun 20 '23 | Sale | 2.74 | 10,000 | 27,390 | 346,478 | Jun 20 05:10 PM | Tuten Scott | Chief Marketing Officer | May 17 '23 | Sale | 3.38 | 10,000 | 33,810 | 356,478 | May 17 05:00 PM | Tuten Scott | Chief Marketing Officer | Apr 17 '23 | Sale | 4.26 | 10,000 | 42,619 | 365,210 | Apr 19 04:40 PM |
|
|
|